| |
BMS032 HCV Protease in Phase 3 Now
|
| |
| |
Another new protease is asunaprevir in later stage development is
Asunaprevir (ASV; BMS-650032), an NS3 Protease Inhibitor, in Combination With Peginterferon and Ribavirin in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C Infection - (04/25/12)
Dual Oral Therapy with NS5A Inhibitor Daclatasvir (BMS-790052) and NS3 Protease Inhibitor Asunaprevir (BMS-650032) in HCV Genotype 1b-Infected Null Responders or Patients Ineligible/Intolerant to Peginterferon/Ribavirin - (04/19/12)
Confirmation That Quadruple Therapy With Daclatasvir (NS5A Inhibitor), Asunaprevir (NS3 Inhibitor) and Peginterferon/Ribavirin Results in a High Rate of SVR4 in HCV Genotype 1 Null Responders - (04/19/12)
HCV Update Selected Highlights: key new HCV drugs, timelines & recent news developments
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) asunaprevir+BMS NS5A
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
This study is currently recruiting participants.
Verified July 2012 by Bristol-Myers Squibb
First Received on April 5, 2012. Last Updated on July 26, 2012
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
This study is currently recruiting participants.
Verified July 2012 by Bristol-Myers Squibb
First Received on April 18, 2012. Last Updated on July 23, 2012
|
|
| |
| |
|
|
|
